Abstract P6-08-03: Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antitumor efficacy of PARP inhibitor in combination with PI3K pathway inhibitor in TNBC xenograft modelXiaoti Lin, Brian Leyland‐Jones, LS Friedman et al.|Cancer Research|2017Cited by 0
Abstract P1-03-02: Preclinical efficacy of a novel and potent inhibitor of the MDM2-p53 axis AMG 232 in ER+ breast cancer modelPK De, B Leyland-Jones, JH Carlson et al.|Cancer Research|2018Cited by 0